Apimeds Pharmaceuticals US (APUS) Cash from Investing Activities (2025)
Apimeds Pharmaceuticals US (APUS) posted Cash from Investing Activities of -$10.0 million for Q4 2025, down 44374.01% on a QoQ basis from -$22540.0 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Cash from Investing Activities (2025) Analysis & Trends
Apimeds Pharmaceuticals US's Cash from Investing Activities history runs 1 years deep, the most recent figure standing at -$10.0 million for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 62.67 Mn | 62.67 Mn | - | -10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.02 Mn |
| Dec 31, 2025 | -10.02 Mn |
| Sep 30, 2025 | -22,540.00 |
| Sep 30, 2025 | -22,540.00 |